Friday, 16 October 2026European Markets

FRANCAISE ENERGIE Stock Was 9.71% Up Today

Loading stream...

(vianews) - the market ended the session with francaise energie (fde.pa) rising 9.71% to €41.80 on wednesday, after three sequential sessions in a row of losses. cac 40 jumped 0.43% to €7,260.73, following the last session's downward trend on what was a somewhat bullish trend trading session today.

francaise energie's last close was €38.10, 27.29% under its 52-week high of €52.40.

about francaise energie

la française de l'energie s.a., together with its subsidiaries, operates as a carbon-negative energy production company in france. it engages in the generation of electricity and heat though photovoltaic plants; purification and liquefaction of biogas, landfill gas, flare gas, rare gases, etc.; and production of bio liquefied natural gas, carbon dioxide, and hydrogen. the company was founded in 2006 and is headquartered in faulquemont, france.

earnings per share

as for profitability, francaise energie has a trailing twelve months eps of €2.31.

pe ratio

francaise energie has a trailing twelve months price to earnings ratio of 18.1. meaning, the purchaser of the share is investing €18.1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.3%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, francaise energie's stock is considered to be overbought (>=80).

moving average

francaise energie's value is higher than its 50-day moving average of €41.45 and higher than its 200-day moving average of €41.79.

more news about francaise energie (fde.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com